Metabolomic profiling highlights oxidative damages in platelet concentrates treated for pathogen inactivation and shows protective role of urate

Metabolomics

Volumn 12, Issue 12, 2016, Pages

  Abonnenc, Mélanie ^a   Crettaz, David ^a   Marvin, Laure ^a   Grund, Baptiste ^b   Sonego, Giona ^a   Bardyn, Manon ^a   Tissot, Jean Daniel ^a   Prudent, Michel ^a   Rochat, Bertrand ^b   Lion, Niels ^a  

^a laboratoire de recherche sur les produits sanguins   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Allantoin; Antioxidant; Mass spectrometry; Metabolomics; Pathogen inactivation; Pathogen reduction; Platelet storage lesion; Urate

Indexed keywords

ALLANTOIN; AMOTOSALEN; GLUTATHIONE; HEMOGLOBIN; NONOXINOL 9; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; THROMBOCYTE CONCENTRATE; URATE; URATE OXIDASE;

ANTIOXIDANT ASSAY; ARTICLE; CONTROLLED STUDY; ELECTROCHEMICAL ANALYSIS; FLOW CYTOMETRY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MASS SPECTROMETRY; METABOLOMICS; NORMAL HUMAN; OXIDATIVE STRESS; PATHOGEN REDUCTION SYSTEM; PURINE METABOLISM; THROMBOCYTE FUNCTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET A RADIATION;

EID: 85002014742     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-1136-0     Document Type: Article

References (52)

1. Abonnenc, M., Crettaz, D., Tacchini, P., Di Vincenzo, L., Sonego, G., Prudent, M., et al. (2016). Antioxidant power as a quality control marker for completeness of amotosalen and ultraviolet A photochemical treatments in platelet concentrates and plasma units. Transfusion, 56(7), 1819–1827. doi:10.1111/trf.13638.
2. Abonnenc, M., Sonego, G., Crettaz, D., Aliotta, A., Prudent, M., Tissot, J. D., et al. (2015a). In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfusion, 55(9), 2219–2230. doi:10.1111/trf.13123.
3. Abonnenc, M., Sonego, G., Kaiser-Guignard, J., Crettaz, D., Prudent, M., Tissot, J. D., et al. (2015b). In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: Psoralen-based photochemical treatment step-by-step. Blood Transfus, 13(2), 255–264. doi:10.2450/2014.0082-14.
4. Abuja, P. M. (1999). Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Letters, 446(2–3), 305–308.
5. Alvarez-Lario, B., & Macarron-Vicente, J. (2010). Uric acid and evolution. Rheumatology (Oxford), 49(11), 2010–2015. doi:10.1093/rheumatology/keq204.
6. Ames, B. N., Cathcart, R., Schwiers, E., & Hochstein, P. (1981). Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA, 78(11), 6858–6862.
7. Amorini, A. M., Tuttobene, M., Tomasello, F. M., Biazzo, F., Gullotta, S., De Pinto, V., et al. (2013). Glucose ameliorates the metabolic profile and mitochondrial function of platelet concentrates during storage in autologous plasma. Blood Transfus, 11(1), 61–70. doi:10.2450/2012.0145-11.
8. Becker, B. F. (1993). Towards the physiological function of uric acid. Free Radical Biology and Medicine, 14(6), 615–631.
9. Bergmeier, W., Piffath, C. L., Cheng, G., Dole, V. S., Zhang, Y., von Andrian, U. H., et al. (2004). Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circulation Research, 95(7), 677–683. doi:10.1161/01.RES.0000143899.73453.11.
10. Bergmeier, W., Rackebrandt, K., Schroder, W., Zirngibl, H., & Nieswandt, B. (2000). Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood, 95(3), 886–893.
11. Brill, A., Chauhan, A. K., Canault, M., Walsh, M. T., Bergmeier, W., & Wagner, D. D. (2009). Oxidative stress activates ADAM17/TACE and induces its target receptor shedding in platelets in a p38-dependent fashion. Cardiovascular Research, 84(1), 137–144. doi:10.1093/cvr/cvp176.
12. Canault, M., Duerschmied, D., Brill, A., Stefanini, L., Schatzberg, D., Cifuni, S. M., et al. (2010). p38 mitogen-activated protein kinase activation during platelet storage: Consequences for platelet recovery and hemostatic function in vivo. Blood, 115(9), 1835–1842. doi:10.1182/blood-2009-03-211706.
13. Cazenave, J. P., Isola, H., Waller, C., Mendel, I., Kientz, D., Laforet, M., et al. (2011). Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: Impact on patient outcomes and component utilization during a 3-year period. Transfusion, 51(3), 622–629. doi:10.1111/j.1537-2995.2010.02873.x.
14. Corash, L., & Sherman, C. D. (2011). Evaluation of platelet transfusion clinical trials. British Journal of Haematology, 153(4), 529–531. doi:10.1111/j.1365-2141.2010.08413.x.
15. Devine, D. V., & Serrano, K. (2010). The platelet storage lesion. Clin Lab Med, 30(2), 475–487. doi:10.1016/j.cll.2010.02.002.
16. Edenbrandt, C. M., & Murphy, S. (1990). Adenine and guanine nucleotide metabolism during platelet storage at 22 degrees C. Blood, 76(9), 1884–1892.
17. Estcourt, L. J. (2014). Why has demand for platelet components increased? A review. Transfusion Medicine, 24(5), 260–268. doi:10.1111/tme.12155.
18. Giustarini, D., Dalle-Donne, I., Milzani, A., Fanti, P., & Rossi, R. (2013). Analysis of GSH and GSSG after derivatization with N-ethylmaleimide. Nature Protocols, 8(9), 1660–1669. doi:10.1038/nprot.2013.095.
19. Greinacher, A., & Hoffmann, W. (2014). Why has the demand for platelet components increased? A commentary. Transfusion Medicine, 24(5), 257–259. doi:10.1111/tme.12154.
20. Holbro, A., Infanti, L., Sigle, J., & Buser, A. (2013). Platelet transfusion: Basic aspects. Swiss Med Wkly, 143, w13885. doi:10.4414/smw.2013.13885.
21. Infanti, L., Stebler, C., Job, S., Ruesch, M., Gratwohl, A., Irsch, J., et al. (2011). Pathogen-inactivation of platelet components with the INTERCEPT blood system: A cohort study. Transfusion and Apheresis Science, 45(2), 175–181. doi:10.1016/j.transci.2011.07.013.
22. Janetzko, K., Cazenave, J. P., Kluter, H., Kientz, D., Michel, M., Beris, P., et al. (2005). Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion, 45(9), 1443–1452. doi:10.1111/j.1537-2995.2005.00550.x.
23. Kaiser-Guignard, J., Canellini, G., Lion, N., Abonnenc, M., Osselaer, J. C., & Tissot, J. D. (2014). The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Reviews, 28(6), 235–241. doi:10.1016/j.blre.2014.07.005.
24. Kerkhoffs, J. L., van Putten, W. L., Novotny, V. M., Te Boekhorst, P. A., Schipperus, M. R., Zwaginga, J. J., et al. (2010). Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. British Journal of Haematology, 150(2), 209–217. doi:10.1111/j.1365-2141.2010.08227.x.
25. Lin, L., Cook, D. N., Wiesehahn, G. P., Alfonso, R., Behrman, B., Cimino, G. D., et al. (1997). Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion, 37(4), 423–435.
26. Lozano, M., Knutson, F., Tardivel, R., Cid, J., Maymo, R. M., Lof, H., et al. (2011). A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. British Journal of Haematology, 153(3), 393–401. doi:10.1111/j.1365-2141.2011.08635.x.
27. Muraoka, S., & Miura, T. (2003). Inhibition by uric acid of free radicals that damage biological molecules. Pharmacology and Toxicology, 93(6), 284–289.
28. Nemkov, T., Hansen, K. C., Dumont, L. J., & D’Alessandro, A. (2016). Metabolomics in transfusion medicine. Transfusion, 56(4), 980–993. doi:10.1111/trf.13442.
29. Osselaer, J. C., Cazenave, J. P., Lambermont, M., Garraud, O., Hidajat, M., Barbolla, L., et al. (2008). An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sanguinis, 94(4), 315–323. doi:10.1111/j.1423-0410.2007.01035.x.
30. Osselaer, J. C., Doyen, C., Defoin, L., Debry, C., Goffaux, M., Messe, N., et al. (2009). Universal adoption of pathogen inactivation of platelet components: Impact on platelet and red blood cell component use. Transfusion, 49(7), 1412–1422. doi:10.1111/j.1537-2995.2009.02151.x.
31. Paglia, G., Sigurjonsson, O. E., Rolfsson, O., Hansen, M. B., Brynjolfsson, S., Gudmundsson, S., et al. (2015). Metabolomic analysis of platelets during storage: A comparison between apheresis- and buffy coat-derived platelet concentrates. Transfusion, 55(2), 301–313. doi:10.1111/trf.12834.
32. Paglia, G., Sigurjonsson, O. E., Rolfsson, O., Valgeirsdottir, S., Hansen, M. B., Brynjolfsson, S., et al. (2014). Comprehensive metabolomic study of platelets reveals the expression of discrete metabolic phenotypes during storage. Transfusion,. doi:10.1111/trf.12710.
33. Perales Villarroel, J. P., Figueredo, R., Guan, Y., Tomaiuolo, M., Karamercan, M. A., Welsh, J., et al. (2013). Increased platelet storage time is associated with mitochondrial dysfunction and impaired platelet function. Journal of Surgical Research, 184(1), 422–429. doi:10.1016/j.jss.2013.05.097.
34. Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C., et al. (1998). An essential role for ectodomain shedding in mammalian development. Science, 282(5392), 1281–1284.
35. Prudent, M., Crettaz, D., Delobel, J., Tissot, J. D., & Lion, N. (2012). Proteomic analysis of Intercept-treated platelets. Journal of Proteomics, 76, 316–328. doi:10.1016/j.jprot.2012.07.008.
36. Prudent, M., D’Alessandro, A., Cazenave, J. P., Devine, D. V., Gachet, C., Greinacher, A., et al. (2014a). Proteome changes in platelets after pathogen inactivation–an interlaboratory consensus. Transfusion Medicine Reviews, 28(2), 72–83. doi:10.1016/j.tmrv.2014.02.002.
37. Prudent, M., Sonego, G., Abonnenc, M., Tissot, J. D., & Lion, N. (2014b). LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. Journal of the American Society for Mass Spectrometry, 25(4), 651–661. doi:10.1007/s13361-013-0813-8.
38. Prudova, A., Serrano, K., Eckhard, U., Fortelny, N., Devine, D. V., & Overall, C. M. (2014). TAILS N-terminomics of human platelets reveals pervasive metalloproteinase-dependent proteolytic processing in storage. Blood, 124(26), e49–e60. doi:10.1182/blood-2014-04-569640.
39. Sano, M., Williams, S., Smith, N., Horne, M., & Gralnick, H. R. (1998). Plasma glycocalicin in platelet concentrates: Relationship to other parameters of the storage lesion. Thrombosis Research, 92(4), 195–198.
40. Santos, C. X., Anjos, E. I., & Augusto, O. (1999). Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Archives of Biochemistry and Biophysics, 372(2), 285–294. doi:10.1006/abbi.1999.1491.
41. Sautin, Y. Y., & Johnson, R. J. (2008). Uric acid: The oxidant-antioxidant paradox. Nucleosides, Nucleotides & Nucleic Acids, 27(6), 608–619. doi:10.1080/15257770802138558.
42. Schlenke, P. (2014). Pathogen inactivation technologies for cellular blood components: an update. Transfusion Medicine and Hemotheraphy, 41(4), 309–325. doi:10.1159/000365646.
43. Schmitz, G., Rothe, G., Ruf, A., Barlage, S., Tschöpe, D., Clemetson, K. J., et al. (1998). European working group on clinical cell analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thrombosis and Haemostasis, 79(5), 885–896.
44. Sevanian, A., Davies, K. J., & Hochstein, P. (1991). Serum urate as an antioxidant for ascorbic acid. American Journal of Clinical Nutrition, 54(6 Suppl), 1129S–1134S.
45. Shrivastava, M. (2009). The platelet storage lesion. Transfusion and Apheresis Science, 41(2), 105–113. doi:10.1016/j.transci.2009.07.002.
46. Sigle, J. P., Infanti, L., Studt, J. D., Martinez, M., Stern, M., Gratwohl, A., et al. (2013). Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion, 53(8), 1788–1797. doi:10.1111/j.1537-2995.2012.03959.x.
47. Tacchini, P., Lesch, A., Neequaye, A., Lagger, G., Liu, J., Cortés-Salazar, F., et al. (2013). Electrochemical pseudo-titration of water-soluble antioxidants. Electroanalysis, 25(4), 922–930.
48. Tzounakas, V. L., Georgatzakou, H. T., Kriebardis, A. G., Papageorgiou, E. G., Stamoulis, K. E., Foudoulaki-Paparizos, L. E., et al. (2015). Uric acid variation among regular blood donors is indicative of red blood cell susceptibility to storage lesion markers: A new hypothesis tested. Transfusion, 55(11), 2659–2671. doi:10.1111/trf.13211.
49. van Rhenen, D., Gulliksson, H., Cazenave, J. P., Pamphilon, D., Ljungman, P., Kluter, H., et al. (2003). Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood, 101(6), 2426–2433. doi:10.1182/blood-2002-03-0932.
50. Xia, J., Psychogios, N., Young, N., & Wishart, D. S. (2009). MetaboAnalyst: A web server for metabolomic data analysis and interpretation. Nucleic Acids Res, 37, W652–W660. doi:10.1093/nar/gkp356.
51. Xia, J., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015). MetaboAnalyst 3.0–making metabolomics more meaningful. Nucleic Acids Research, 43(W1), W251–W257. doi:10.1093/nar/gkv380.
52. Zimring, J. C., Slichter, S., Odem-Davis, K., Felcyn, J. R., Kapp, L. M., Bell, L. N., et al. (2016). Metabolites in stored platelets associated with platelet recoveries and survivals. Transfusion,. doi:10.1111/trf.13631.